Literature DB >> 2348645

HIV infection in intravenous drug abusers in Berlin: risk factors and time trends.

K Stark1, R Müller, I Guggenmoos-Holzmann, S Deininger, E Meyer, U Bienzle.   

Abstract

To investigate the epidemiology of HIV infection among intravenous drug abusers (IVDA) in Berlin (West), from October 1984 to October 1988, 741 heterosexual IVDA were recruited from facilities for drug treatment and counseling. In this group 22.8% were seropositive for antibodies against HIV, representing 21.1% of the females and 23.5% of the males. Seroprevalences of hepatitis B, hepatitis A, and lues were 67.7%, 40.1%, and 4.0%, respectively. Seropositivity for HIV antibodies correlated with positive seromarkers for hepatitis B and A, and with certain behavioral and social features such as sharing of injection equipment, imprisonment, and intravenous drug use in prison. The crude time trend of HIV seroprevalence shows an increase from 17.1% in those subjects who discontinued i.v. drug abuse in 1983 or earlier to 31.5% in 1985, and a decrease over the past 3 years to 14.1% in 1988. After adjusting for temporary changes in the study group, the estimated HIV seroprevalence odds show an almost steady increase and were significantly higher for those who were injecting drugs in 1987 and 1988 compared with those who stopped i.v. drug use before 1984. Thus IVDA with a persistent risk profile are at a still-increasing risk of acquiring HIV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2348645     DOI: 10.1007/bf01648583

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

1.  Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers.

Authors:  J R Robertson; A B Bucknall; P D Welsby; J J Roberts; J M Inglis; J F Peutherer; R P Brettle
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-22

2.  Update: acquired immunodeficiency syndrome associated with intravenous-drug use--United States, 1988.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1989-03-17       Impact factor: 17.586

3.  Intravenous drug use and the heterosexual transmission of the human immunodeficiency virus. Current trends in New York City.

Authors:  D C Des Jarlais; E Wish; S R Friedman; R Stoneburner; S R Yancovitz; D Mildvan; W el-Sadr; E Brady; M Cuadrado
Journal:  N Y State J Med       Date:  1987-05

Review 4.  HIV infection among intravenous drug users: epidemiology and risk reduction.

Authors:  D C Des Jarlais; S R Friedman
Journal:  AIDS       Date:  1987-07       Impact factor: 4.177

5.  High frequency of HTLV-III antibodies among heterosexual intravenous drug abusers in the Austrian Tyrol.

Authors:  D Fuchs; H G Blecha; F Deinhardt; M P Dierich; F D Goebel; P Hengster; H Hinterhuber; D Schoenitzer; K Traill; H Wachter
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

6.  Which anti-HTLV III/LAV assays for screening and confirmatory testing?

Authors:  P P Mortimer; J V Parry; J Y Mortimer
Journal:  Lancet       Date:  1985-10-19       Impact factor: 79.321

7.  HTLV-III antibody in Swiss and English intravenous drug abusers.

Authors:  P P Mortimer; E M Vandervelde; W J Jesson; M S Pereira; F Burkhardt
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

8.  HTLV-III antibody in drug abusers in the west of Scotland: the Edinburgh connection.

Authors:  E A Follett; A McIntyre; B O'Donnell; G B Clements; U Desselberger
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

9.  Syphilis, hepatitis A and hepatitis B seromarkers in homosexual men.

Authors:  C H Coester; U Bienzle; H G Hoffmann; E Koehn; I Guggenmoos-Holzmann
Journal:  Klin Wochenschr       Date:  1984-09-03

10.  Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco.

Authors:  R E Chaisson; A R Moss; R Onishi; D Osmond; J R Carlson
Journal:  Am J Public Health       Date:  1987-02       Impact factor: 9.308

View more
  3 in total

1.  HIV infection in prisons. High risk behaviour is common in prisons in Berlin.

Authors:  R Müller; K Stark; I Guggenmoos-Holzmann
Journal:  BMJ       Date:  1995-05-13

2.  HIV-1-prevalence in fatalities from Hamburg, Germany.

Authors:  U Lockemann; W Schulz-Schaeffer; F Wischhusen; R Laufs; K Püschel
Journal:  Int J Legal Med       Date:  1993       Impact factor: 2.686

3.  Clinical care of the HIV-infected drug user.

Authors:  R Douglas Bruce; Frederick L Altice
Journal:  Infect Dis Clin North Am       Date:  2007-03       Impact factor: 5.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.